EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Statin use and colorectal cancer prognosis: an updated systematic review and meta-analysis

Tao Jiang, Jiaxin Wu, Lichao Fan, Wenjiang Wu, Xuesong Tang, Zhigang Xu, Linchong Yu, Shijun Xia

Frontiers in Oncology · 09.11.2026 · 16

DOI: 10.3389/fonc.2026.1920835 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 09.11.2026. Verfasst von Tao Jiang und 7 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Statins are affordable and commonly prescribed, but their impact on mortality in patients with colorectal cancer (CRC) remains unclear.

Methods

A systematic search of PubMed, Embase, and the Cochrane Library identified English-language studies on statin use and CRC mortality published through March 2025. Adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs) were pooled to calculate summary HRs. Heterogeneity was assessed using the Q-test and I 2 statistic, applying fixed-effects models for I 2 <50% and random-effects models for I 2 ≥50%. Subgroup analyses explored sources of heterogeneity.

Results

Twenty studies involving 207, 041 patients with CRC were included. Ten studies (131, 599 patients) evaluated prediagnostic statin use, and 13 studies (75, 442 patients) evaluated postdiagnostic statin use. For prediagnostic use, fixed-effects models yielded pooled HRs of 0.87 (95% CI, 0.81–0.92) for all-cause mortality (ACM) and 0.82 (95% CI, 0.78–0.86) for cancer-specific mortality (CSM). For postdiagnostic use, random-effects models showed pooled HRs of 0.81 (95% CI, 0.73–0.89) for ACM and 0.76 (95% CI, 0.69–0.84) for CSM. Subgroup analyses revealed significant differences in ACM by region, tumor location, and follow-up duration with notable findings in European patients. A statistically significant difference was observed between studies with ≥5 years of follow-up and between stage I–III patients. Sensitivity analyses restricted to studies using time-dependent Cox regression produced consistent estimates for both cancer-specific and all-cause mortality.

Conclusion

Prediagnostic and postdiagnostic statin use were associated with reduced ACM and CSM in patients with CRC. However, given the observational nature of the included studies and the potential for residual confounding, these findings should be interpreted as associations rather than causal effects, and they require confirmation in large-scale, prospective randomized trials.

Zitieren

APA

Jiang, T., Wu, J., Fan, L., Wu, W., Tang, X., Xu, Z., Yu, L., & Xia, S. (2026). Statin use and colorectal cancer prognosis: an updated systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1920835

Vancouver

Jiang T, Wu J, Fan L, Wu W, Tang X, Xu Z, et al. Statin use and colorectal cancer prognosis: an updated systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1920835

BibTeX
@article{Jiang2026,
  author = {Jiang, Tao and Wu, Jiaxin and Fan, Lichao and Wu, Wenjiang and Tang, Xuesong and Xu, Zhigang and Yu, Linchong and Xia, Shijun},
  title = {Statin use and colorectal cancer prognosis: an updated systematic review and meta-analysis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1920835}
}
Kostenlos starten →